Advitech researches, develops, and commercializes nutraceutical ingredients and products to prevent immune-mediated inflammatory disorders.
Advitech is a life science and technology company with the mission to discover and commercialize patented, scientifically supported natural health products. Effective and safe, these products target immune system disorders, such as psoriasis and inflammatory bowel disease. Advitech produces Dermylex (R) for the treatment of mild to moderate psoriasis. Advitech has developed a research program to develop new applications in the field of wound healing. This development program stems from the two technological platforms XP-828L and IM.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 26, 2009 | Series Unknown | $2.51M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
AgeChem Venture Fund | — | Series Unknown |